Compare Neurocrine Biosciences Inc (NBIX) vs T-Mobile Us Inc (TMUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs T-Mobile Us Inc — how do they compare? Neurocrine Biosciences Inc trades at $155.5 (market cap $15.77B), while T-Mobile Us Inc trades at $178.67 (market cap $190.23B). The key difference: T-Mobile Us Inc is far larger — about 12.1× Neurocrine Biosciences Inc's market cap, and T-Mobile Us Inc pays a 2.3% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | TMUS | |
|---|---|---|
Market Cap | $15.77B | $190.23B |
Sector | Health | Media |
52-Week High | $185.50 | $241.67 |
52-Week Low | $123.10 | $167.65 |
Enterprise Value | $15.78B | $306.84B |
Dividend Yield | — | 2.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
T-Mobile US (TMUS) trades at $181.69, showing minimal daily movement with a 0.09% gain. The stock faces bearish technical signals but maintains strong fundamentals with consistent revenue growth from $81.4B in 2024 to $88.3B in 2025 and robust profitability margins. Recent earnings show mixed results with Q1 and Q2 2026 beats but a Q4 2025 miss. The company announced a CFO transition effective February 2027 and continues strategic partnerships, including the Paramount+ Plaza naming rights deal announced September 8, 2026.
TMUS presents a compelling long-term opportunity with 80% analyst buy ratings and a $233.20 consensus price target implying 28% upside. However, rising debt levels (debt-to-asset ratio increased to 39.35% in 2025) and competitive broadband pricing pressures pose risks. The stock's valuation at 19x P/E appears reasonable given sector positioning and growth trajectory, though technical weakness suggests near-term consolidation may continue.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →
